Decongestiva (neusontzwellers) voor het ontzwellen van de neusholte, om schade aan het neusslijmvlies en neusbloedingen bij intubatie door de neus te voorkomen

Decongestants for dilating the nasal cavity, a randomised, blinded, prospective study to prevent iatrogenic epistaxis during nasotracheal intubation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20173

Enrollment

180

Registered

2014-08-13

Start date

2014-08-18

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epistaxis Nasal intubation

Interventions

Patients in the intervention group will be prepared for anesthesia and surgery, according standard of care. 60 minutes before the planned surgery the patient will receive xylomethazoline intranasally

Eligibility

Inclusion criteria

Inclusion criteria: Age older than 18 years Nasal intubation indicated and required for the planned surgery Informed consent

Exclusion criteria

Exclusion criteria: Age less than 18 years old COPD Gold 3 or 4 Severe dyspnoe (History of) nasal trauma or anatomical deformities Known allergy to any of the medications used

Design outcomes

Secondary

Measure	Time frame
• Number of attempts • Resistance during intubation • Difficulty of intubation (grade of intubation) • Evaluation of nasal complications: o Persistent nasal bleeding o Nasal pain (NRS-score) o Nasal trauma o Difficulty of nasal breathing	—

Primary

Measure	Time frame
•Severity of the epistaxis: onone/slight/moderate/severe orequiring suction: yes/no •Navigability of the tube during nasal passage (smooth or impinged)	—

Contacts

Public ContactR.A. Bouwman

arthur.bouwman@catharinaziekenhuis.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)